A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
Key facts
- Who runs it
- Visirna Therapeutics HK Limited
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- NCT05902598
- U1111-1330-5258
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 37 people enrolled
- Started
- 10 Jul 2023
- Ended
- 9 Jan 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Plozasiran
- Placebon
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Males or nonpregnant (who do not plan to become pregnant), nonlactating females ≥18 years of age
- Fasting triglycerides (TG) ≥10 mmol/L (~880 mg/dL) at screening, that is refractory to standard lipid lowering therapy (sample drawn after at least the minimum time on stable lipid-lowering regimen described in protocol). Two repeat tests are allowed to qualify
- A diagnosis of FCS
- Willing to follow dietary counseling as per PI judgment based on local standard of care, consistent with an intake of ≤20 g of fat per day during the study
- If on medications for management of type 2 diabetes, or other medications specified in protocol, the dosing regimen must be stable before collection of qualified lipid parameter at screening
- Participants with a medical history of clinical atherosclerotic cardiovascular disease (ASCVD) or those with elevated 10-year ASCVD risk (eg, ≥7.5% per American Heart Association / American College of Cardiology risk calculator) must be on appropriate lipid-lowering therapy as per local standard of care (ie, including moderate to high intensity statin, as indicated) prior to collection of qualifying TG levels
- Participants of childbearing potential must agree to use a highly effective form of contraception in addition to a male condom, during the study and for at least 24 weeks after the last dose of investigational product (IP). Women of childbearing potential on a hormonal contraceptive must be stable on the medication for ≥1 menstrual cycles prior to Day 1. Men must not donate sperm during the study and for at least 24 weeks after the last dose of IP
Who cannot take part
- Active pancreatitis within 12 weeks before Day 1
- History of acute coronary syndrome event within 24 weeks of Day 1; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
- Diabetes mellitus with any of the following:; Newly diagnosed within 12 weeks of screening; HbA1c ≥9.0% at screening
- Current use or use within the last 365 days from Day 1 of any hepatocyte-targeted siRNA or antisense oligonucleotide molecule
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, double-blinded, placebo controlled, two periods phase 3 clinical study. The primary objective of the study was to evaluate the efficacy and safety of Plozasiran injection in Chinese adults with familial chylomicronemia syndrome (FCS). A total of 37 participants were enrolled in the study. The duration of the study randomized period was approximately 112 weeks, including a screening period of up to 8 weeks and a treatment period of up to 104 weeks. Participants who completed the randomized period will continue in a 1-year open-label extension period where all participants will receive Plozasiran.
The 3 groups in the trial
- Plozasiran 25 mgTreatment being tested
Plozasiran 25 mg administered every 3 months for 12 months (randomized period), followed by an open-label period of 12 months
Treatment: Plozasiran
- Plozasiran 50 mgTreatment being tested
Plozasiran 50 mg administered every 3 months for 12 months (randomized period), followed by an open-label period of 12 months
Treatment: Plozasiran
- PlaceboPlacebo, for comparison
Matching placebo administered every 3 months for 12 months
Treatment: Placebon
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 / VSA001 / SAR449124 Injection in Chinese Adults With Familial Chylomicronemia Syndrome
- Record updated
- 17 November 2026